TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3287912

Group type: EXPERIMENTAL
Intervention: Piroxicam 40 mg once daily for the first two days followed by 20 mg once daily for the remainder of the study (14 days, minimum 7 days, maximum 28 days)
Number of subjects: 1290

Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 1290

Group type: COMPARATOR
Intervention: Aspirin 4 g per day for the duration of the study
Number of subjects: 1290

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily for two days followed by 250 mg in the morning and 500 mg in the evening thereafter
Number of subjects: 1290

Group type: COMPARATOR
Intervention: Indomethacin 50 mg three times per day for two days and 25 mg three times per day thereafter
Number of subjects: 1290
Study: 31800559

Group type: EXPERIMENTAL
Intervention: Combined intense pulsed light and radiofrequency (E‐light)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nd:YAG laser
Number of subjects: 50
Study: 29880562

Group type: EXPERIMENTAL
Intervention: Peer-led home-education intervention with 5 home visits from a trained peer counsellor discussing infant care and nutrition.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Presence of paternal grandmothers during the intervention.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 12
Study: 28704343

Group type: EXPERIMENTAL
Intervention: HIPP intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: wellness contact control
Number of subjects: 84
Study: 26207975

Group type: EXPERIMENTAL
Intervention: Weight-bearing biofeedback training (part of standard-of-care rehabilitation)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard-of-care rehabilitation (control group)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Weight-bearing biofeedback training
Number of subjects: 26
Study: 24106935

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (5 to 6 liters per minute)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Nasal CPAP (7 cm of water)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae
Number of subjects: 303

Group type: COMPARATOR
Intervention: Nasal CPAP
Number of subjects: 303
Study: 20938636

Group type: EXPERIMENTAL
Intervention: Endurance exercise-training for 10 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 26
Study: 17713471

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/RTV)
Number of subjects: 7
Study: 17032094

Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 60
Study: 15107719

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 506

Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 506
Study: 11202838

Group type: EXPERIMENTAL
Intervention: Increase group (maintained EMG activity above 10 microV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Decrease group (maintained EMG activity below 2 microV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 9287260

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. and clarithromycin 500 mg t.d.s. for two weeks (n = 27)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: De‐Nol 240 mg b.d. for four weeks, metronidazole 400 mg t.d.s. and amoxicillin 500 mg t.d.s. for one week (n = 26)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. and amoxicillin 500 mg t.d.s. for two weeks (n = 26)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Traditional 'triple' therapy with bismuth and two antibiotics
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hp eradication
Number of subjects: 79
Study: 8320401

Group type: EXPERIMENTAL
Intervention: Intensive therapy with dietary adherence support from dietitians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Role of dietitians in recruiting and selecting study volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietitians' involvement in promoting dietary adherence
Number of subjects: 0
Study: 3549320

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily + Ibuprofen 400 mg t.i.d. for 4 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily + Diclofenac 25 mg t.i.d. for 4 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily + Sulindac 200 mg b.i.d. for 4 weeks
Number of subjects: 8
Study: 28901660

Group type: EXPERIMENTAL
Intervention: Local steroid injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wrist splinting
Number of subjects: 50
Study: 26872281

Group type: EXPERIMENTAL
Intervention: Cephalometric measures in Class I patients
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Cephalometric measures in Class II patients
Number of subjects: 108

Group type: COMPARATOR
Intervention: Objective measurements on lateral cephalograms
Number of subjects: 108
Study: 24726507

Group type: EXPERIMENTAL
Intervention: Removal of cerclage
Number of subjects: 56

Group type: COMPARATOR
Intervention: Retention of cerclage
Number of subjects: 56
Study: 23817285

Group type: EXPERIMENTAL
Intervention: Nursing-led pain and symptom management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current usual care
Number of subjects: 0
Study: 20575298

Group type: EXPERIMENTAL
Intervention: Guo's Maqian decoction (200 ml, twice daily for 8 weeks, followed by Guokangning capsule (0.44 g per capsule, 2 capsules, three times daily for 4 weeks))
Number of subjects: 114

Group type: COMPARATOR
Intervention: Basic treatment including calcium supplementation and herb decoction
Number of subjects: 114
Study: 18669951

Group type: EXPERIMENTAL
Intervention: HIV infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Highly active anti-retroviral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other factors (e.g., reduced body mass index, suboptimal nutrition, anti-retroviral drugs)
Number of subjects: 0
Study: 15992724

Group type: EXPERIMENTAL
Intervention: Irrigated catheter ablation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard catheter ablation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 26
Study: 12891224

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (30 to 46 mg/kg/day, given twice daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 109

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 109

Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 109
Study: 10566573

Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg, titrated to 20 mg if necessary
Number of subjects: 177

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg, titrated to 20 mg if necessary
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 177

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 177
Study: 9499813

Group type: EXPERIMENTAL
Intervention: Bronchial histamine and methacholine challenges
Number of subjects: 10
Study: 1809994

Group type: EXPERIMENTAL
Intervention: Lubor ampouls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lubor cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Voltaren
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketonal cream
Number of subjects: 0
Study: 6340000

Group type: EXPERIMENTAL
Intervention: Fosfolip (calcium salt of phosphorylcholine chloride with pantethine) 3 capsules a day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (25 checks)
Number of subjects: 50
Study: 31260089

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) adjunctive therapy (400‐1200 mg once daily)
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) adjunctive therapy
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) monotherapy (1200‐1600 mg once daily)
Number of subjects: 1812

Group type: COMPARATOR
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 1812
Study: 29579102

Group type: EXPERIMENTAL
Intervention: Pills rich in n‐3 PUFA
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 27980393

Group type: EXPERIMENTAL
Intervention: Paracetamol (APAP) 2 g
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24172656

Group type: EXPERIMENTAL
Intervention: Physiotherapy-led exercise program (7 exercises daily for 12 weeks)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Dexamethasone injection followed by daily calf stretching
Number of subjects: 56
Study: 23217397

Group type: EXPERIMENTAL
Intervention: IPC + GCS
Number of subjects: 108

Group type: COMPARATOR
Intervention: GCS
Number of subjects: 108
Study: 20716080

Group type: EXPERIMENTAL
Intervention: Bupivacaine-tramadol (1 mg x kg(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine-neostigmine (2 microg x kg(‐1))
Number of subjects: 60
Study: 17720116

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided facet joint injections
Number of subjects: 40

Group type: COMPARATOR
Intervention: CT-controlled facet joint injections
Number of subjects: 40
Study: 16385303

Group type: EXPERIMENTAL
Intervention: Closed intramedullary nailing (Group I)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Open reduction and internal fixation with plates and screws (Group II)
Number of subjects: 64
Study: 12087139

Group type: EXPERIMENTAL
Intervention: lopinavir-ritonavir (400 mg of lopinavir plus 100 mg of ritonavir twice daily)
Number of subjects: 653

Group type: COMPARATOR
Intervention: nelfinavir (750 mg three times daily)
Number of subjects: 653
Study: 10215095

Group type: EXPERIMENTAL
Intervention: Complete forebrain commissurotomy (L.B.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Posterior callosotomy (D.K.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 8
Study: 7833482

Group type: EXPERIMENTAL
Intervention: Reticulocyte indices
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Correlation between red cell and reticulocyte indices
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: MCV ratio
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Inversion of MCV ratio
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Reticulocyte volume during marrow transplantation
Number of subjects: 190
Study: 2798694

Group type: EXPERIMENTAL
Intervention: Highly motivated subjects
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Lying (act of deception)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Verbal response (affirming, denying, repeating, or no verbal response)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Repeated questions
Number of subjects: 232

Group type: COMPARATOR
Intervention: Electrodermal measures
Number of subjects: 232
Study: 355732

Group type: EXPERIMENTAL
Intervention: D-penicillamine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 30370532

Group type: EXPERIMENTAL
Intervention: Prolonged exercise training (12-week program: resistance exercise twice per week, high intensity interval training once per week)
Number of subjects: 14
Study: 27811523

Group type: EXPERIMENTAL
Intervention: 2% concentration of fluorescein
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10% concentration of fluorescein
Number of subjects: 22

Group type: COMPARATOR
Intervention: Both concentrations
Number of subjects: 22
Study: 26093486

Group type: EXPERIMENTAL
Intervention: Bipolar sealer
Number of subjects: 118
Study: 23871417

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m² every 21 days, intravenously) with Atrasentan (10 mg/day, orally)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m² every 21 days, intravenously) with Placebo
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Docetaxel with Atrasentan
Number of subjects: 994

Group type: COMPARATOR
Intervention: Docetaxel with Placebo
Number of subjects: 994
Study: 21825080

Group type: EXPERIMENTAL
Intervention: 17.5 mg once-weekly risedronate
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo (combined with daily 1000 IU of ergocalciferol)
Number of subjects: 272
Study: 19309475

Group type: EXPERIMENTAL
Intervention: Exchange transfusion (XC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Simple transfusion (ST)
Number of subjects: 20
Study: 17080507

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg IR formulation)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Optimized extraction method (control)
Number of subjects: 1
Study: 15809368

Group type: EXPERIMENTAL
Intervention: Intensive atorvastatin to reduce LDL to <80 mg/dL (n=96)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Intensive atorvastatin to reduce LDL to <80 mg/dL plus antioxidant vitamins C (1000 mg/d) and E (800 mg/d) (n=101)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Diet and low-dose lovastatin to reduce LDL to <130 mg/dL (n=103; control group)
Number of subjects: 300
Study: 12197292

Group type: EXPERIMENTAL
Intervention: Stapling hemorrhoidectomy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional surgery (open or closed)
Number of subjects: 90
Study: 10211493

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (acupoint group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia with morphine (acupoint group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patient-controlled analgesia with morphine (control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Postoperative complications (acupoint group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Postoperative complications (control group)
Number of subjects: 60
Study: 7628595

Group type: COMPARATOR
Intervention: ZDV (500 mg daily) alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ZDV (500 mg daily) with folinic acid (15 mg daily) and intramuscular vitamin B12 (1000 micrograms monthly)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ZDV (500 mg daily) with folinic acid and vitamin B12
Number of subjects: 60
Study: 2703006

Group type: EXPERIMENTAL
Intervention: LMF + BCG
Number of subjects: 254

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 254
Study: 824172

Group type: EXPERIMENTAL
Intervention: 10 mg sublingual isosorbide dinitrate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31576436

Group type: EXPERIMENTAL
Intervention: Levosimendan 0.2 µg/kg/min continuous infusion
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 28177480

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with bevacizumab (4 cycles of FEC followed by 4 cycles of docetaxel for HER2-negative tumours in BEVERLY-1; docetaxel and trastuzumab for HER2-positive tumours in BEVERLY-2)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: CTC detection at baseline (≥1 CTC/7.5 ml)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Combination of pCR after neoadjuvant treatment with no CTC detection at baseline
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: CEC level at baseline or variations during treatment
Number of subjects: 152
Study: 25988734

Group type: EXPERIMENTAL
Intervention: Digitized tracing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Digital photography
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 20
Study: 23176189

Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol pMDI without VHC
Number of subjects: 16

Group type: COMPARATOR
Intervention: Budesonide-formoterol pMDI with VHC
Number of subjects: 16
Study: 21440864

Group type: EXPERIMENTAL
Intervention: CD34+ transplantation (SC group)
Number of subjects: 55
Study: 19401663

Group type: EXPERIMENTAL
Intervention: VAP technique (4 applications of 2 ml lidocaine 2% with oxygen flow of 3 l min(‐1))
Number of subjects: 34

Group type: COMPARATOR
Intervention: STAN technique (insufflation of 3 l min(‐1) oxygen via nasal probe and two applications of 4 ml of lidocaine 2%)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: VAP technique
Number of subjects: 34
Study: 15384821

Group type: EXPERIMENTAL
Intervention: NEPP regimen (1 exchange of Nutrineal, 1 exchange of Extraneal, 2 exchanges of Physioneal)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard PD (SPD) regimen (4 exchanges of Dianeal)
Number of subjects: 74
Study: 10379018

Group type: EXPERIMENTAL
Intervention: Budesonide (400 microg, twice daily)
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1277
Study: 8924304

Group type: EXPERIMENTAL
Intervention: Health promotion programmes screened via closed circuit television in hospital waiting rooms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal television programmes screened on non-programme days
Number of subjects: 0
Study: 2202199

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) suppositories, 400 mg bid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 30
Study: 7225493

Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30849296

Group type: EXPERIMENTAL
Intervention: Caloric restriction plus exercise (CR + EX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exercise (EX) only
Number of subjects: 60
Study: 27377616

Group type: EXPERIMENTAL
Intervention: Lidocaine/prilocaine cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lidocaine/tetracaine cream
Number of subjects: 30
Study: 26303453

Group type: EXPERIMENTAL
Intervention: Sexual health education (intervention group, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (control group, n=30)
Number of subjects: 60
Study: 25251749

Group type: EXPERIMENTAL
Intervention: Individual phone participation (IC)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Group phone participation (CC)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Participants with EDS
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Anti-depressant use (ADMs)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: High stress
Number of subjects: 257
Study: 22926301

Group type: EXPERIMENTAL
Intervention: Circulating retinol
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Retinol levels
Number of subjects: 1433
Study: 19322907

Group type: EXPERIMENTAL
Intervention: Immunomodulators for patients at moderate risk of recurrence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologic therapy (antitumor necrosis factor agents) for patients at highest risk of recurrence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colonoscopy 6-12 months after surgery
Number of subjects: 0
Study: 17394986

Group type: EXPERIMENTAL
Intervention: Moderate procedural sedation (PS) target
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Deep procedural sedation (PS) target
Number of subjects: 75
Study: 15542184

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 729

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 729
Study: 11412051

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 22

Group type: COMPARATOR
Intervention: NCEP-1 diet
Number of subjects: 22
Study: 9783557

Group type: EXPERIMENTAL
Intervention: Morning light (10,000 lux, 30 min/d)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Evening light (10,000 lux, 30 min/d)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High-density negative air ionization (2.7 x 10(6) ions/cm³, 30 min/d in the morning)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Low-density negative air ionization (1.0 x 10(4) ions/cm³, 30 min/d in the morning)
Number of subjects: 158
Study: 8006284

Group type: EXPERIMENTAL
Intervention: Captopril (75 mg daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29290017

Group type: EXPERIMENTAL
Intervention: Weight bearing exercise (WBE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Resistance exercise (RE)
Number of subjects: 19
Study: 27894540

Group type: EXPERIMENTAL
Intervention: AcceleDent (20 minutes a day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: AcceleDent sham device
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fixed appliances only
Number of subjects: 81
Study: 25613949

Group type: EXPERIMENTAL
Intervention: Telemetric intraocular pressure (IOP) sensor implantation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Telemetric IOP measurement
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Self-tonometry at home
Number of subjects: 6
Study: 23758456

Group type: EXPERIMENTAL
Intervention: Visible-light curing of pulp capping compounds (Groups 1-7)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diode laser irradiation without prior application of a pulp capping compound (Groups 8-10)
Number of subjects: 100
Study: 21963329

Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA
Number of subjects: 153

Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 153
Study: 19285304

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion for the first 24 hours after surgery
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 22
Study: 17079189

Group type: EXPERIMENTAL
Intervention: Long-acting nifedipine
Number of subjects: 7665

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7665
Study: 15096083

Group type: EXPERIMENTAL
Intervention: 7000 lux (active) light box
Number of subjects: 10

Group type: COMPARATOR
Intervention: 500 lux (placebo) light box
Number of subjects: 10
Study: 11518073

Group type: EXPERIMENTAL
Intervention: St. John's wort (Ze 117; 500 mg extract/day)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 240
Study: 9457399

Group type: EXPERIMENTAL
Intervention: High-dose intravenous rIL-2 alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose intravenous rIL-2 plus rIFN-alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-dose outpatient subcutaneous rIL-2 plus rIFN-alpha
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient rIL-2/rIFN-alpha plus 5-FU/rIFN-alpha
Number of subjects: 0